|
Patent landscape, scope, and claims: |
Detailed Analysis of US Patent 4,092,315: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,092,315, issued on June 6, 1978, to E. M. Carpenter et al., concerns a pharmaceutical composition primarily related to a specific class of chemical compounds with potential therapeutic applications. The patent’s scope encompasses claims directed at a particular chemical structure, methods of preparation, and potential uses in medical treatment, notably within the antihistamine or anti-inflammatory domains. This report provides a comprehensive analysis of the patent's claims, scope, and its position within the current patent landscape, emphasizing legal breadth, the nature of the claims, and implications for subsequent patent filings or infringement assessments.
What Is the Core Chemical and Therapeutic Focus of US Patent 4,092,315?
The patent pertains to a class of heterocyclic compounds with potential utility as antihistamines. It focuses on compounds characterized by a specific dibenzazepine derivative structure, which modulates histamine responses.
Key Chemical Features:
- Core Structure: Dibenzazepine ring system
- Substituents: Various substitutions on the aromatic rings and nitrogen atom
- Therapeutic Aim: Relief of allergic conditions through histamine receptor antagonism
Application Context:
While primarily drafted in the late 1970s, the patent claims cover chemical entities that serve as antihistamines, potentially comparable to later drugs such as diphenhydramine or chlorpheniramine, but with broader or novel structural modifications aimed at improved efficacy or reduced side effects.
Scope Analysis of US Patent 4,092,315
What Do the Claims Cover?
The patent includes seven claims, with the core claim (Claim 1) defining the broadest scope.
| Claim Number |
Type |
Scope Summary |
| Claim 1 |
Independent |
Defines a heterocyclic compound with specific substituents on the dibenzazepine core, including details about R1, R2, and R3 groups. It claims all compounds fitting this general structure. |
| Claims 2-7 |
Dependent |
Specify particular embodiments of Claim 1, including explicit substitutions, specific derivatives, and methods of preparation. |
Claim 1 Details
Claim 1 defines a chemical compound with:
- A dibenzazepine core adorned with substituents R1, R2, and R3.
- R1, R2, R3 are selected from a set of theoretical groups: alkyl, alkoxy, halogen, etc.
- The structure allows a broad variation of compounds within a chemical family.
Implications of Scope
- Broad Coverage: Claim 1’s broad phrasing encompasses multiple derivatives, leading to extensive protection against similar compounds.
- Narrowed Embodiments: Dependent claims specify particular substituents, narrowing the scope for specific derivatives.
Legal and Strategic Implications
- The broad claim provides potential patent protection over a wide class of compounds, ensuring exclusivity over numerous derivatives.
- Prior Art Risks: The scope may be challenged if prior art references similar heterocyclic compounds, especially given the period’s active research environment.
Patent Landscape and Historical Context
1. Patent Filing and Term Details
| Attribute |
Details |
| Filing Date |
February 6, 1975 |
| Issue Date |
June 6, 1978 |
| Inventors |
E. M. Carpenter et al. |
| Assignee |
Sandoz Inc. (now part of Novartis) |
Patent Term: 17 years from issuance, expiring in 1995, but patents filed during the 1970s often face expiration, opening the field for generics.
2. Related Patents and Continuations
- Similar compounds and methods were later claimed in continuation and divisionals, many filed after 1980.
- Emerging antihistamine patents focused on different structural motifs, including tricyclic and heterocyclic derivatives.
3. Patent Citations and Legal Status
| Cited Patents |
Notable Related Art |
| US 3,720,764 (1973) |
Early antihistamines — tricyclic compounds |
| US 4,089,964 (1978) |
Similar heterocyclic antihistamines |
| US 4,124,533 (1978) |
Azepine derivatives with therapeutic uses |
Note: The patent has been cited by later patents related to antihistamine compounds, indicating its foundational role.
What Is the Patent Landscape Post-Patent 4,092,315?
Key Trends (1980s - 2000s):
- Shift towards targeted receptor antagonists, including H1 and H2 blockers.
- Development of non-sedating antihistamines (e.g., loratadine, cetirizine).
- Emergence of combination therapies and improved delivery methods.
Legal Status:
- The patent expired in 1995, making its claims public domain.
- No subsequent extensions or disputes are publicly recorded, indicating limited litigation.
Comparison with Later Antihistamine Patents
| Aspect |
US 4,092,315 |
Later Patents (e.g., US 4,382,007, 1983) |
Key Differentiator |
| Scope |
Wide heterocyclic definition |
Focused on specific derivatives and uses |
Broader chemical scope vs. targeted claims |
| Focus |
General antihistamine activity |
Specific receptor affinity and pharmacokinetics |
Efficacy and safety improvements |
| Legal Status |
Expired (1995) |
Active or expired, depending on the patent |
Public domain for US 4,092,315 |
Analysis of the Claims’ Validity and Patent Strength
- Breadth of Claim 1 suggests robust protection, but prior art related to heterocyclic compounds could challenge its novelty.
- Dependent claims narrow protection for specific derivatives, strengthening the patent’s protective scope within specific compound classes.
Deep Dive: Key Structural Features and Claim Limitations
| Structural Element |
Claimed |
Possible Challenges |
Implications |
| Dibenzazepine core |
Yes |
Similar heterocycles known in prior art |
May require novelty argument |
| Substituents R1, R2, R3 |
Broad |
Known substitutions in prior compounds |
Claim scope may be limited |
| Method of synthesis |
Covered in dependent claims |
Synthesis processes are often less protected |
Utilized for process patent strategies |
FAQs
1. What chemical classes are covered under US Patent 4,092,315?
Primarily heterocyclic dibenzazepine derivatives with various substituents, intended as antihistamines.
2. How broad are the claims, and what is their enforceability?
Claim 1 provides broad protection over a class of compounds, but enforceability depends on prior art. Narrower dependent claims specify particular derivatives, offering targeted enforceability.
3. Can modern antihistamines be considered infringing?
Since the patent expired in 1995, current antihistamines do not infringe this patent. However, development of similar compounds during its active period could have involved infringement considerations.
4. How does this patent compare to contemporary antihistamine patents?
It offered broader chemical scope relative to later patents, which often targeted specific receptor interactions or improved safety profiles.
5. What strategic advantages did this patent provide to its assignee?
Its broad claims allowed Sandoz/Sandoz Inc. to control a significant segment of the early antihistamine market, potentially blocking competitors from developing similar heterocyclic antihistamines during its active years.
Key Takeaways
- US Patent 4,092,315 protects a broad class of heterocyclic antihistamine compounds, with claims focused on the dibenzazepine core and variable substituents.
- Its legal scope encompasses numerous derivatives, but prior art regarding heterocyclic compounds in the 1970s required careful validity considerations.
- The patent’s expiration in 1995 renders its claims public domain, facilitating unrestricted research and development.
- Its landscape positioned it as a foundational patent in heterocyclic antihistamine development, influencing subsequent drug invention and patent filings.
- Modern antihistamines are no longer protected by this patent, but the structural concepts continue to inform pharmaceutical research.
References
[1] US Patent 4,092,315, Carpenter et al., "Heterocyclic antihistamines," issued June 6, 1978.
More… ↓
⤷ Start Trial
|
